| Autor: |
Angela Ayén-Rodríguez, Laura Linares-González, Carlos Llamas-Segura, Francisco Manuel Almazán-Fernández, Ricardo Ruiz-Villaverde |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
International Journal of Environmental Research and Public Health. 20:5824 |
| ISSN: |
1660-4601 |
| DOI: |
10.3390/ijerph20105824 |
| Popis: |
Background: Basal cell carcinoma (BCC) is the most common type of skin cancer and can represent a therapeutic challenge in patients with locally advanced disease. Vismodegib is a hedgehog pathway inhibitor approved by the FDA for use in this type of tumor. We present a case series to describe our experience with the use of vismodegib. Methods: A retrospective study that included patients treated with vismodegib at our dermatology unit was conducted. Monthly follow-up was performed, and we registered the clinical evolution and adverse reactions. Results: A total of six patients with locally advanced BCCs were included (50% males and 50% females), with a mean age of 78.5 years old. The treatment was administered over a mean of 5 months. A complete response was observed in four cases and partial response in two cases. No recurrence was detected, with a median follow-up duration after discontinuation of 18 months. Most patients (83%) had at least one adverse event, and two needed dose adjustment temporarily or permanently to continue. The main adverse effect was muscle spasms (66.7%). The main limitation of our study was the small sample, which was not representative of the general population. Conclusions: Vismodegib is a safe and effective treatment for locally advanced BCC, and its role in unresectable BCC seems to be an important option in these challenging cases. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
